000172851 001__ 172851
000172851 005__ 20210129214522.0
000172851 0247_ $$2doi$$a10.1212/WNL.0000000000000799
000172851 0247_ $$2ISSN$$a0028-3878
000172851 0247_ $$2ISSN$$a1526-632X
000172851 0247_ $$2WOS$$aWOS:000342230700016
000172851 037__ $$aFZJ-2014-06285
000172851 082__ $$a610
000172851 1001_ $$0P:(DE-HGF)0$$aSchneider, C.$$b0$$eCorresponding Author
000172851 245__ $$aPrimary intracranial plasma cell granuloma responsive to rituximab
000172851 260__ $$aHagerstown, Md.$$bLippincott Williams & Wilkins$$c2014
000172851 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1437391731_27741
000172851 3367_ $$2DataCite$$aOutput Types/Journal article
000172851 3367_ $$00$$2EndNote$$aJournal Article
000172851 3367_ $$2BibTeX$$aARTICLE
000172851 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000172851 3367_ $$2DRIVER$$aarticle
000172851 520__ $$aPlasma cell granuloma (PCG) is a sporadically occurring tumor-like mass that is histologically characterized by a non-neoplastic proliferation of inflammatory cells. The predominant cell types in PCG are polyclonal plasma cells and their precursors, including a substantial amount of mature B cells. 
000172851 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000172851 588__ $$aDataset connected to CrossRef, juser.fz-juelich.de
000172851 7001_ $$0P:(DE-HGF)0$$aHenning, T. D.$$b1
000172851 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b2$$ufzj
000172851 7001_ $$0P:(DE-HGF)0$$aSchroeter, M.$$b3
000172851 7001_ $$0P:(DE-HGF)0$$aLehmann, H. C.$$b4
000172851 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000000799$$gVol. 83, no. 12, p. 1119 - 1120$$n12$$p1119 - 1120$$tNeurology$$v83$$x1526-632X$$y2014
000172851 909CO $$ooai:juser.fz-juelich.de:172851$$pVDB
000172851 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000172851 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bPOF III$$lKey Technologies$$vDecoding the Human Brain$$x0
000172851 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000172851 9141_ $$y2014
000172851 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000172851 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000172851 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000172851 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000172851 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5
000172851 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000172851 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000172851 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000172851 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000172851 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000172851 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000172851 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000172851 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000172851 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000172851 980__ $$ajournal
000172851 980__ $$aVDB
000172851 980__ $$aI:(DE-Juel1)INM-3-20090406
000172851 980__ $$aUNRESTRICTED